254
Participants
Start Date
April 30, 2009
Primary Completion Date
June 28, 2018
Study Completion Date
October 9, 2018
Lenalidomide
"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
Investigators choice single agent
Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
UZ Brussels, Brussels
Rigshospitalet Department of Haematology L4042, Copenhagen
Herlev Hospital, Herlev
Cliniques Universitaires UCL de Mont-Godine, Yvoir
Medisch Spectrum Twente, Enshede
Isala Klinieken, Zwolle
Hospital Universitario Vall D Hebron, Barcelona
AZ Groeninge, Kortrijk
UZ Gent, Ghent
Attikon General University Hospital of Athens, Athens
Charles University General Hospital, Prague
Institut Paoli-Calmettes, Marseille
Azienda Ospedaliera Universitaria San Martino, Genova
Istituto Europeo di Oncologia - IEO, Milan
San Raffaele Scientific Institute, Milan
Lund University Hosptial, Lund
University of Patras, Pátrai
I.R.C.C.S. Policlinico San Matteo, Pavia
Hospital de La Princesa, Madrid
Hospital La Paz, Madrid
Hospital Costa del Sol, Marbella
Clinica Universitaria de Navarra, Pamplona
Polyclinique Bordeaux Nord Aquitaine Service Onco-Hematologie, Bordeaux
CHRU - Hopital du Haut Leveque, Pessac
CHU Montpellier - Hôpital Saint Eloi, Montpellier
CHU Rennes Hematology, Rennes
Rambam Medical Center, Haifa
UKG Universitatsklinikum Gottingen, Göttingen
CHU Hopital Michallon, Grenoble
Ospedale Regionale di Bolzano, Bolzano
A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna
CHRU - Hotel Dieu, Nantes
Universitatsklinikum Essen, Essen
Universitatsklinik Munster, Münster
Rabin Medical Center, Petah Tikva
Uniklinik Koln, Cologne
Sheba Medical Center, Tel Litwinsky
CHRU Hopitaux de Brabois, Vandœuvre-lès-Nancy
Ospedale S. Chiara, Pisa
CHRU-Hopital Claude Huriez, Lille
Hotel Dieu, Clermont-Ferrand
Universitatsklinikum des Saarlandes, Homburg-Saar
Hopital civil, Strasbourg
CHRU Hôpital de Hautepierre, Strasbourg
Centre Leon Berard, Lyon
Centre Hospitalier Lyon Sud, Pierre-Bénite
A.O. Policlinico - Università di Bari, Bari
IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
Clinique Victor Hugo, Le Mans
Ematologia ed Immunologia, Lecce
Hopital Saint-Louis, Paris
University Hospital Uppsala, Uppsala
Stadtisches Klinikum Karlsruhe, Karlsruhe
Centre Henri Becquerel, Rouen
Universitaetsklinikum FreiburgInnere Med.1, Haematologie, Freiburg im Breisgau
Centre Hospitalier Departemental Les Oudrairies, La Roche-sur-Yon
Reference Cancer Center of Basilicata, Rionero in Vulture
CHU Dupuytren, Limoges
University of Ulm, Ulm
"Azienda Ospedaliera Bianchi-Melacrino-Morelli", Reggio Calabria
Az. Osp. Vincenzo Cervello, Palermo
Hadassah University Hospital, Jerusalem
Ospedale Ferrarotto, Catania
Institution of Russian Academy of Medical Sciences Russian Oncological Research Centre n.a. N. N. Bl, Moscow
St. Petersburg Research Institute of Hematology and Blood Transfusion, Saint Petersburg
St. Petersburg Pavlov State Medical University, Saint Petersburg
Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, Saint Petersburg
Medical Radiology Research Centre RAMS, Obninsk
Scientific Research Institute of OncologySoft Tissue Department, Rostov-on-Don
Volgograd Regional Clinical Oncology Dispensary 1, Volgograd
Republic Clinical Oncology Dispensary, Kazan'
Nizhegorodskiy Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod
Perm Territorial Oncology Dispensary, Perm
Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg
Novosibirsk State Regional Clinical Hospital, Novosibirsk
Teaching Hospital BrnoHemato-oncology Dept, Brno
University Hospital2.Dep. of Int.med. hematology, Hradec Králové
Centre Antoine Lacassagne Oncologie medicale et Hematologie, Nice
Asklepios Klinik St. Georg, Hamburg
Az. Osp di Perugia, Perugia
Meander Medisch Centrum, Amersfoort
Malopolskie Centrum medyczne s.c., Krakow
Uniwersytet Jagiellonski Collegium Medicum, Krakow
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warsaw
Nowotworww Krwi i Transplantacji Szpiku, Wroclaw
Dolnoslaskie Centrum Transplantacji Komorkowych, Wroclaw
Saratov Medical University Chair of Professional Pathology and Haematology, Saratov
Royal Bournemouth Hosp, Bournemouth
Addenbrookes Hospital, Cambridge
Royal Liverpool University Hospital, Liverpool
Christie Hospital, Manchester
Newcastle Hospital Foundation Trust, Newcastle upon Tyne
John Radcliffe Hospital, Oxford
Derriford Hospital, Plymouth
Southampton General Hospital, Southampton
The Royal Wolverhampton Hospital NHS Trust, Wolverhampton
Lead Sponsor
Celgene
INDUSTRY